Literature DB >> 11465726

Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).

C A D'Arcy1, M Mannik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11465726     DOI： 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  20 in total

Review 1.  From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.

Authors:  G R Gunn; D C F Sealey; F Jamali; B Meibohm; S Ghosh; G Shankar
Journal:  Clin Exp Immunol       Date:  2016-01-19       Impact factor: 4.330

Review 2.  Update on rituximab.

Authors:  R Eisenberg
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Serum sickness with refractory nephrotic syndrome following treatment with rituximab.

Authors:  Ryo Maeda; Yukihiko Kawasaki; Shinichiro Ohara; Kazuhide Suyama; Mitsuaki Hosoya
Journal:  CEN Case Rep       Date:  2018-01-05

Review 4.  Susceptibility to adverse drug reactions.

Authors:  Robin Ferner; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

5.  Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Authors:  G Shankar; S Arkin; L Cocea; V Devanarayan; S Kirshner; A Kromminga; V Quarmby; S Richards; C K Schneider; M Subramanyam; S Swanson; D Verthelyi; S Yim
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

6.  Systemic adverse events following rituximab therapy in patients with Graves' disease.

Authors:  D El Fassi; C H Nielsen; P Junker; H C Hasselbalch; L Hegedüs
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

7.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Authors:  Raphaèle Seror; Christelle Sordet; Loic Guillevin; Eric Hachulla; Charles Masson; Marc Ittah; Sophie Candon; Véronique Le Guern; Achille Aouba; Jean Sibilia; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

8.  TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Authors:  Osman N Yogurtcu; Zuben E Sauna; Joseph R McGill; Million A Tegenge; Hong Yang
Journal:  AAPS J       Date:  2019-08-02       Impact factor: 4.009

Review 9.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 10.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.